Bernardo H. Goulart, MD, MS of Seattle Cancer Care Alliance discusses the use of natural language processing (NLP) for patients with non-small cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Abstract 6528: Validation of natural language processing (NLP) for automated ascertainment of EGFR and ALK tests in SEER cases of non-small cell lung cancer (NSCLC).
Advertisement